ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 130 filers reported holding ARRAY BIOPHARMA INC in Q2 2014. The put-call ratio across all filers is 0.73 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $181,000 | -23.9% | 21,670 | -18.7% | 0.01% | -28.6% |
| Q1 2017 | $238,000 | +17.2% | 26,638 | +15.5% | 0.01% | +40.0% |
| Q4 2016 | $203,000 | +141.7% | 23,061 | -2.5% | 0.01% | +150.0% |
| Q2 2016 | $84,000 | -47.5% | 23,641 | -56.4% | 0.00% | -60.0% |
| Q1 2016 | $160,000 | -65.6% | 54,268 | -50.8% | 0.01% | -37.5% |
| Q4 2015 | $465,000 | +440.7% | 110,271 | +487.3% | 0.01% | +700.0% |
| Q3 2015 | $86,000 | -33.8% | 18,777 | +4.1% | 0.00% | -50.0% |
| Q2 2015 | $130,000 | -65.3% | 18,043 | -64.5% | 0.00% | -75.0% |
| Q1 2015 | $375,000 | +77.7% | 50,826 | +14.1% | 0.01% | +166.7% |
| Q4 2014 | $211,000 | +95.4% | 44,562 | +46.8% | 0.00% | +50.0% |
| Q3 2014 | $108,000 | -61.6% | 30,356 | -50.9% | 0.00% | -50.0% |
| Q2 2014 | $281,000 | +215.7% | 61,826 | +227.1% | 0.00% | +300.0% |
| Q1 2014 | $89,000 | +39.1% | 18,902 | +48.7% | 0.00% | 0.0% |
| Q4 2013 | $64,000 | -54.9% | 12,715 | -44.4% | 0.00% | -50.0% |
| Q3 2013 | $142,000 | – | 22,873 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Redmile Group, LLC | 16,618,776 | $146,079,000 | 12.59% |
| BVF INC/IL | 4,986,186 | $43,829,000 | 8.81% |
| First Light Asset Management, LLC | 1,000,361 | $8,793,000 | 3.86% |
| Crosspoint Capital Strategies, LLC | 463,005 | $4,070,000 | 3.62% |
| Consonance Capital Management LP | 2,723,471 | $23,912,000 | 2.63% |
| KOPP INVESTMENT ADVISORS LLC | 219,926 | $1,933,000 | 2.04% |
| SPHERA FUNDS MANAGEMENT LTD. | 900,000 | $7,911,000 | 2.00% |
| Orbimed Advisors | 16,088,800 | $141,421,000 | 1.80% |
| Cormorant Asset Management, LP | 1,150,000 | $10,109,000 | 1.36% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,073,680 | $18,227,000 | 1.26% |